chemotherapy; elderly; frailty; ovarian cancer; surgery
Abstract :
[en] Elderly women with ovarian cancer are often undertreated due to a perception of frailty. We aimed to evaluate the management of young, elderly and very elderly patients and its impact on survival in a retrospective multicenter study of women with ovarian cancer between 2007 to 2015. We included 979 women: 615 women (62.8%) <65 years, 225 (22.6%) 65-74 years, and 139 (14.2%) ≥75 years. Women in the 65-74 years age group were more likely to have serous ovarian cancer (p = 0.048). Patients >65 years had more >IIa FIGO stage: 76% for <65 years, 84% for 65-74 years and 80% for ≥75 years (p = 0.033). Women ≥75 years had less standard procedures (40% (34/84) vs. 59% (104/177) for 65-74 years and 72% (384/530) for <65 years (p < 0.001). Only 9% (13/139) of women ≥75 years had an Aletti score >8 compared with 16% and 22% for the other groups (p < 0.001). More residual disease was found in the two older groups (30%, respectively) than the younger group (20%) (p < 0.05). Women ≥75 years had fewer neoadjuvant/adjuvant cycles than the young and elderly women: 23% ≥75 years received <6 cycles vs. 10% (p = 0.003). Univariate analysis for 3-year Overall Survival showed that age >65 years, FIGO III (HR = 3.702, 95%CI: 2.30-5.95) and IV (HR = 6.318, 95%CI: 3.70-10.77) (p < 0.001), residual disease (HR = 3.226, 95%CI: 2.51-4.15; p < 0.001) and lymph node metastasis (HR = 2.81, 95%CI: 1.91-4.12; p < 0.001) were associated with lower OS. Women >65 years are more likely to have incomplete surgery and more residual disease despite more advanced ovarian cancer. These elements are prognostic factors for women's survival regardless of age. Specific trials in the elderly would produce evidence-based medicine and guidelines for ovarian cancer management in this population.
Disciplines :
Oncology
Author, co-author :
Joueidi, Yolaine
Dion, Ludivine
Bendifallah, Sofiane
Mimoun, Camille
Bricou, Alexandre
Nyangoh Timoh, Krystel
Collinet, Pierre
Touboul, Cyril
Ouldamer, Lobna
Azaïs, Henri
Dabi, Yohann
Akladios, Cherif
Canlorbe, Geoffroy
Bolze, Pierre-Adrien
Costaz, Hélène
Mezzadri, Mathieu
Gauthier, Tristan
Kridelka, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie-Obstétrique
Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–E386. [CrossRef] [PubMed]
Cesari, M.; Cerullo, F.; Zamboni, V.; Di Palma, R.; Scambia, G.; Balducci, L.; Antonelli Incalzi, R.; Vellas, B.; Gambassi, G. Functional status and mortality in older women with gynecological cancer. J. Gerontol. A Biol. Sci. Med. Sci 2013, 68, 1129–1133. [CrossRef] [PubMed]
Aletti, G.D.; Dowdy, S.C.; Podratz, K.C.; Cliby, W.A. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am. J. Obstet. Gynecol. 2007, 197, 676-e1. [CrossRef] [PubMed]
Wright, J.D.; Chen, L.; Tergas, A.I.; Patankar, S.; Burke, W.M.; Hou, J.Y.; Neugut, A.I.; Ananth, C.V.; Hershman, D.L. Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet. Gynecol 2015, 125, 1345–1352. [CrossRef] [PubMed]
Ries, L.A. Ovarian cancer. Survival and treatment differences by age. Cancer 1993, 71, 524–529. [CrossRef] [PubMed]
Howlader, N.; Ries, L.A.; Mariotto, A.B.; Reichman, M.E.; Ruhl, J.; Cronin, K.A. Improved estimates of cancer-specific survival rates from population-based data. J. Natl. Cancer Inst. 2010, 102, 1584–1598. [CrossRef]
Bristow, R.E.; Tomacruz, R.S.; Armstrong, D.K.; Trimble, E.L.; Montz, F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J. Clin. Oncol. 2002, 20, 1248–1259. [CrossRef]
Moore, K.N.; Reid, M.S.; Fong, D.N.; Myers, T.K.; Landrum, L.M.; Moxley, K.M.; Walker, J.L.; McMeekin, D.S.; Mannel, R.S. Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol. Oncol. 2008, 110, 133–139. [CrossRef]
Alberts, D.S.; Dahlberg, S.; Green, S.J.; Garcia, D.; Hannigan, E.V.; O’toole, R.; Stock-Novack, D.; Surwit, E.A.; Malviya, V.K.; Jolles, C.J. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer 1993, 71, 618–627. [CrossRef]
Yancik, R.; Ries, L.G.; Yates, J.W. Ovarian cancer in the elderly: An analysis of surveillance, epidemiology, and end results program data. Am. J. Obstet. Gynecol. 1986, 154, 639–647. [CrossRef]
Hightower, R.D.; Nguyen, H.N.; Averette, H.E.; Hoskins, W.; Harrison, T.; Steren, A. National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients. Cancer 1994, 73, 377–383. [CrossRef]
Díaz-Montes, T.P.; Zahurak, M.L.; Giuntoli II, R.L.; Gardner, G.J.; Gordon, T.A.; Armstrong, D.K.; Bristow, R.E. Surgical care of elderly women with ovarian cancer: A population-based perspective. Gynecol. Oncol. 2005, 99, 352–357. [CrossRef] [PubMed]
Cloven, N.G.; Manetta, A.; Berman, M.L.; Kohler, M.F.; DiSaia, P.J. Management of ovarian cancer in patients older than 80 years of Age. Gynecol. Oncol. 1999, 73, 137–139. [CrossRef] [PubMed]
Thigpen, T.; Brady, M.F.; Omura, G.A.; Creasman, W.T.; McGuire, W.P.; Hoskins, W.J.; Williams, S. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993, 71, 606–614. [CrossRef]
Lewis, J.H.; Kilgore, M.L.; Goldman, D.P.; Trimble, E.L.; Kaplan, R.; Montello, M.J.; Housman, M.G.; Escarce, J.J. Participation of patients 65 years of age or older in cancer clinical trials. J. Clin. Oncol. Oncol. 2003, 21, 1383–1389. [CrossRef]
Markman, M.; Lewis, J.L., Jr.; Saigo, P.; Hakes, T.; Jones, W.; Rubin, S.; Reichman, B.; Barakat, R.; Curtin, J.; Almadrones, L. et al. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1993, 71, 634–637. [CrossRef]
Edwards, B.K.; Howe, H.L.; Ries, L.A.; Thun, M.J.; Rosenberg, H.M.; Yancik, R.; Wingo, P.A.; Jemal, A.; Feigal, E.G. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002, 94, 2766–2792. [CrossRef]
Hightower, C.E.; Riedel, B.J.; Feig, B.W.; Morris, G.S.; Ensor, J.E., Jr.; Woodruff, V.D.; Daley-Norman, M.D.; Sun, X.G. A pilot study evaluating predictors of postoperative outcomes after major abdominal surgery: Physiological capacity compared with the ASA physical status classification system. Br. J. Anaesth. 2010, 104, 465–471. [CrossRef]
Hohn, A.K.; Einenkel, J.; Wittekind, C.; Horn, L.C. New FIGO classification of ovarian, fallopian tube and primary peritoneal cancer. Pathologe 2014, 35, 322–326. [CrossRef]
Luyckx, M.; Leblanc, E.; Filleron, T.; Morice, P.; Darai, E.; Classe, J.M.; Ferron, G.; Stoeckle, E.; Pomel, C.; Vinet, B.; et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: A retrospective French multicentric study. Int. J. Gynecol. Cancer 2012, 22, 1337–1343. [CrossRef]
Dindo, D.; Demartines, N.; Clavien, P.A. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 2004, 240, 205–213. [CrossRef] [PubMed]
Uyar, D.; Frasure, H.E.; Markman, M.; Von Gruenigen, V.E. Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol. Oncol. Oncol. 2005, 98, 403–408. [CrossRef] [PubMed]
Sundararajan, V.; Hershman, D.; Grann, V.R.; Jacobson, J.S.; Neugut, A.I. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: A population-based study. J. Clin. Oncol. 2002, 20, 173–178. [CrossRef] [PubMed]
Yancik, R.; Moore, T.D.; Martin, G.; Obrams, G.I.; Reed, E. Older women as the focus for research and treatment of ovarian cancer. An overview for the National Institute on Aging, National Cancer Institute, and American Cancer Society Multidisciplinary Working Conference. Cancer 1993, 71, 514–516. [CrossRef]
Kuhn, W. Clinical trials in elderly ovarian cancer patients—Does it make sense? Onkologie 2012, 35, 73–74. [CrossRef]
Tortorella, L.; Vizzielli, G.; Fusco, D.; Cho, W.C.; Bernabei, R.; Scambia, G.; Colloca, G. Ovarian cancer management in the oldest old: Improving outcomes and tailoring treatments. Aging Dis. 2017, 8, 677–684. [CrossRef]
Shenoy, P.; Harugeri, A. Elderly patients’ participation in clinical trials. Perspect Clin. Res. 2015, 6, 184–189. [CrossRef] [PubMed]
Warren, J.L.; Harlan, L.C.; Trimble, E.L.; Stevens, J.; Grimes, M.; Cronin, K.A. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study. Gynecol. Oncol. 2017, 145, 486–492. [CrossRef]
Gershenson, D.M.; Mitchell, M.F.; Atkinson, N.; Silva, E.G.; Burke, T.W.; Morris, M.; Kavanagh, J.J.; Warner, D.; Wharton, J.T. Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer 1993, 71, 638–643. [CrossRef]
Hutchins, L.F.; Unger, J.M.; Crowley, J.J.; Coltman, C.A.; Albain, K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 1999, 341, 2061–2067. [CrossRef]
Yee, K.W.; Pater, J.L.; Pho, L.; Zee, B.; Siu, L.L. Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier? J. Clin. Oncol. 2003, 21, 1618–1623. [CrossRef]
Trimble, E.L.; Carter, C.L.; Cain, D.; Freidlin, B.; Ungerleider, R.S.; Friedman, M.A. Representation of older patients in cancer treatment trials. Cancer 1994, 74, 2208–2214. [CrossRef]
Ferrero, A.; Fuso, L.; Tripodi, E.; Tana, R.; Daniele, A.; Zanfagnin, V.; Perotto, S.; Gadducci, A. Ovarian cancer in elderly patients: Patterns of care and treatment outcomes according to age and modified frailty index. Int. J. Gynecol. Cancer 2017, 27, 1863–1871. [CrossRef] [PubMed]
Ceccaroni, M.; D’Agostino, G.; Ferrandina, G.; Gadducci, A.; Di Vagno, G.; Pignata, S.; Poerio, A.; Salerno, M.G.; Fanucchi, A.; Lapresa, M.T.; et al. Gynecological malignancies in elderly patients: Is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol. Oncol. Oncol. 2002, 85, 445–450. [CrossRef] [PubMed]
Villella, J.; Chalas, E. Optimising treatment of elderly patients with ovarian cancer: Improving their enrollment in clinical trials. Drugs Aging 2005, 22, 95–100. [CrossRef] [PubMed]
Bruchim, I.; Altaras, M.; Fishman, A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol. Oncol. Oncol. 2002, 86, 274–278. [CrossRef] [PubMed]
Eisenhauer, E.L.; Tew, W.P.; Levine, D.A.; Lichtman, S.M.; Brown, C.L.; Aghajanian, C.; Huh, J.; Barakat, R.R.; Chi, D.S. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol. Oncol. 2007, 106, 381–387. [CrossRef]
Hershman, D.; Fleischauer, A.T.; Jacobson, J.S.; Grann, V.R.; Sundararajan, V.; Neugut, A.I. Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: A population-based study. Gynecol. Oncol. 2004, 92, 293–299. [CrossRef]
Hilpert, F.; du Bois, A.; Greimel, E.R.; Hedderich, J.; Krause, G.; Venhoff, L.; Loibl, S.; Pfisterer, J. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged > or =70 years with advanced ovarian cancer—A study by the AGO OVAR Germany. Ann. Oncol. 2007, 18, 282–287. [CrossRef]
Fairfield, K.M.; Murray, K.; Lucas, F.L.; Wierman, H.R.; Earle, C.C.; Trimble, E.L.; Small, L.; Warren, J.L. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. J. Clin. Oncol. 2011, 29, 3921–3926. [CrossRef] [PubMed]
Amadio, G.; Marchetti, C.; Villani, E.R.; Fusco, D.; Stollagli, F.; Bottoni, C.; Distefano, M.; Colloca, G.; Scambia, G.; Fagotti, A. ToleRability of BevacizUmab in elderly ovarian cancer patients (TURBO study): A case-control study of a real-life experience. J. Gynecol. Oncol. 2020, 31, e6. [CrossRef] [PubMed]
Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; Kurzeder, C.; et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011, 365, 2484–2496. [CrossRef] [PubMed]
Yancik, R. Cancer burden in the aged: An epidemiologic and demographic overview. Cancer 1997, 80, 1273–1283. [CrossRef]
Chereau, E.; Ballester, M.; Selle, F.; Rouzier, R.; Darai, E. Ovarian cancer in the elderly: Impact of surgery on morbidity and survival. Eur. J. Surg. Oncol. 2011, 37, 537–542. [CrossRef] [PubMed]
Alphs, H.H.; Zahurak, M.L.; Bristow, R.E.; Diaz-Montes, T.P. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol. Oncol. 2006, 103, 1048–1053. [CrossRef]
Woopen, H.; Inci, G.; Richter, R.; Chekerov, R.; Ismaeel, F.; Sehouli, J. Elderly ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO). Eur. J. Cancer 2016, 60, 101–106. [CrossRef]
Bristow, R.E.; Zahurak, M.L.; Diaz-Montes, T.P.; Giuntoli, R.L.; Armstrong, D.K. Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol. Oncol. 2009, 115, 334–338. [CrossRef]
Lavoue, V.; Huchon, C.; Akladios, C.; Alfonsi, P.; Bakrin, N.; Ballester, M.; Bendifallah, S.; Bolze, P.A.; Bonnet, F.; Bourgin, C.; et al. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology. J. Gynecol. Obstet. Hum. Reprod. 2019, 48, 369–378.
Lavoue, V.; Huchon, C.; Akladios, C.; Alfonsi, P.; Bakrin, N.; Ballester, M.; Bendifallah, S.; Bolze, P.A.; Bonnet, F.; Bourgin, C.; et al. Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: Systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up). J. Gynecol. Obstet. Hum. Reprod. 2019, 48, 379–386.
Harter, P.; Sehouli, J.; Lorusso, D.; Reuss, A.; Vergote, I.; Marth, C.; Kim, J.W.; Raspagliesi, F.; Lampe, B.; Aletti, G.; et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N. Engl. J. Med. 2019, 380, 822–832. [CrossRef] [PubMed]
Moore, K.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 2018, 379, 2495–2505. [CrossRef] [PubMed]
Van Driel, W.J.; Koole, S.N.; Sikorska, K.; Schagen van Leeuwen, J.H.; Schreuder, H.W.; Hermans, R.H.; De Hingh, I.H.; Van Der Velden, J.; Arts, H.J.; Massuger, L.F.; et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med. 2018, 378, 230–240. [CrossRef] [PubMed]